Forbion Secures Record €2.3 Billion Across Two Funds, Offering Critical Boost to European Biotech Sector
admin The Netherlands-based venture capital firm Forbion has successfully closed two new funds, Forbion Growth Opportunities...
fda
Sanofi and Regeneron Fortify Immunology Alliance with Focus on Next-Generation IL-4/IL-13 Inhibitors, Bolstering Pipeline Against Patent Expiry
Paris, France, and Tarrytown, New York – In a strategic move designed to extend their...
The European Association for the Study of Diabetes Annual Meeting Illuminates Next-Generation Obesity Treatments and Intensifying Pharmaceutical Race
Milan, Italy – The annual meeting of the European Association for the Study of Diabetes...
Pharmaceutical Industry Reshapes Leadership and Bolsters Pipelines with Key Approvals and Strategic Acquisitions
The biopharmaceutical sector is experiencing a period of significant strategic realignment, marked by a high-profile...
Roche’s Fenebrutinib Faces Regulatory Scrutiny Despite Landmark FDA Application Acceptance for Multiple Sclerosis.
The U.S. Food and Drug Administration (FDA) has accepted Roche’s application for fenebrutinib, a Bruton’s...
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
Bristol Myers Squibb (BMS) has confirmed that its investigational drug, admilparant, an LPA1 receptor inhibitor,...
Beam Therapeutics Files Landmark Trade Secret Lawsuit Against YolTech and Serapha Bio Over Alleged IP Theft in Gene Editing.
In a high-stakes legal battle poised to send ripples across the burgeoning gene editing industry,...
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
London, UK & Cambridge, MA – In a significant move set to reshape a segment...
Kodiak Sciences’ Zenkuda Emerges as Potent Rival to Regeneron’s Eylea, Reshaping the Multi-Billion Dollar Retinal Disease Market
In a landmark announcement that sent ripples through the biopharmaceutical industry, Kodiak Sciences has unveiled...
Merck and Daiichi Sankyo Withdraw I-DXd Application for Small-Cell Lung Cancer Amidst Evolving Competitive Landscape and Increased Regulatory Scrutiny
The landscape of oncology drug development is a relentless arena of innovation, competition, and regulatory...
